Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Crinetics Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Crinetics Pharmaceuticals (CRNX – Research Report), ...

Analysts’ Top Healthcare Picks: Crinetics Pharmaceuticals (CRNX), Denali Therapeutics (DNLI)

The latest announcement is out from Crinetics Pharmaceuticals ( ($CRNX) ). On January 5, 2026, Crinetics Pharmaceuticals reported strong early U.S....

Crinetics Highlights Strong PALSONIFY Launch and Trial Progress

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crinetics Pharmaceuticals (CRNX – Research Report)...

Market Cap	$5.41B	P/E Ratio	N/A
52W High	$57.99	52W Low	$24.10
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-9.6%	52W Position	74.9%
Overall Score	60	Value Score	60
Quality Score	55	Technical Score	66

EPS Current Est	$-5.03	EPS Next Est	$-5.32
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CRNX	$49.48	+0.26%	555.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CRNX	$49.48	+0.3%	555.40K
3
4
5
6

CRNX

CRNX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Crinetics Pharmaceuticals Inc. Data in Excel

Get Crinetics Pharmaceuticals Inc. Data in Excel